CL2019001618A1 - Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. - Google Patents

Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.

Info

Publication number
CL2019001618A1
CL2019001618A1 CL2019001618A CL2019001618A CL2019001618A1 CL 2019001618 A1 CL2019001618 A1 CL 2019001618A1 CL 2019001618 A CL2019001618 A CL 2019001618A CL 2019001618 A CL2019001618 A CL 2019001618A CL 2019001618 A1 CL2019001618 A1 CL 2019001618A1
Authority
CL
Chile
Prior art keywords
relief
prevention
treatment
bipolar disorder
carbamate compounds
Prior art date
Application number
CL2019001618A
Other languages
English (en)
Spanish (es)
Inventor
Yu Jin Shin
Sei Myoung Han
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2019001618A1 publication Critical patent/CL2019001618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2019001618A 2016-12-14 2019-06-12 Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. CL2019001618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14

Publications (1)

Publication Number Publication Date
CL2019001618A1 true CL2019001618A1 (es) 2019-08-23

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001618A CL2019001618A1 (es) 2016-12-14 2019-06-12 Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.

Country Status (14)

Country Link
US (1) US11571410B2 (https=)
EP (1) EP3556366B1 (https=)
JP (1) JP7208139B2 (https=)
KR (1) KR102635938B1 (https=)
CN (1) CN110290788A (https=)
AU (1) AU2017374458B2 (https=)
BR (1) BR112019011930A2 (https=)
CL (1) CL2019001618A1 (https=)
ES (1) ES3054693T3 (https=)
IL (1) IL267195B2 (https=)
MX (1) MX2019006940A (https=)
MY (1) MY199104A (https=)
WO (1) WO2018111008A1 (https=)
ZA (1) ZA201903747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
BR112022009533A2 (pt) * 2019-11-22 2022-08-02 Sk Biopharmaceuticals Co Ltd Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL192029B1 (pl) * 1997-08-14 2006-08-31 Hoffmann La Roche Zastosowanie heterocyklicznych eterów winylowych, nowe heterocykliczne etery winylowe, sposób ich wytwarzania i środek farmaceutyczny
CN1251758C (zh) 2000-07-21 2006-04-19 特瓦制药工业有限公司 丙戊酸和2－丙基戊烯酸酰胺的衍生物在制备治疗双极情感障碍症躁狂病药物中的用途
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder
ES2262801T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar.
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
WO2010150946A1 (en) 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
EP3556366B1 (en) 2025-10-22
CN110290788A (zh) 2019-09-27
IL267195A (https=) 2019-07-31
AU2017374458B2 (en) 2023-03-02
JP7208139B2 (ja) 2023-01-18
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
WO2018111008A1 (ko) 2018-06-21
IL267195B1 (en) 2024-01-01
US11571410B2 (en) 2023-02-07
CA3046297A1 (en) 2018-06-21
US20190314337A1 (en) 2019-10-17
MX2019006940A (es) 2019-09-06
JP2020502106A (ja) 2020-01-23
ZA201903747B (en) 2021-01-27
KR20190087572A (ko) 2019-07-24
RU2019121913A (ru) 2021-01-15
ES3054693T3 (en) 2026-02-05
BR112019011930A2 (pt) 2019-10-29
AU2017374458A1 (en) 2019-07-04
MY199104A (en) 2023-10-13
KR102635938B1 (ko) 2024-02-13
RU2019121913A3 (https=) 2021-04-21

Similar Documents

Publication Publication Date Title
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2019000266A1 (es) Composición de cannabis.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
JOP20210050A1 (ar) معدلات تعبير pnpla3
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.